These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 12899120)
1. Postmarketing drug dosage changes. Peck CC Pharmacoepidemiol Drug Saf; 2003; 12(5):425-6. PubMed ID: 12899120 [No Abstract] [Full Text] [Related]
2. Current status of the drug safety monitoring system in Korea. Park BJ Pharmacoepidemiol Drug Saf; 2001; 10(6):557-60. PubMed ID: 11828840 [No Abstract] [Full Text] [Related]
3. [Cost/benefit analysis of a regional drug surveillance center]. Mignot G; Chichmanian RM; Spreux A; Bernard G Therapie; 1988; 43(5):377-8. PubMed ID: 3147546 [No Abstract] [Full Text] [Related]
4. Measuring adverse drug reactions in a postmarketing surveillance system. Fisher S; Bryant SG; Kluge RM Psychopharmacol Bull; 1986; 22(1):272-7. PubMed ID: 3726073 [No Abstract] [Full Text] [Related]
6. An underrecognized challenge in evaluating postmarketing drug safety. Roden DM Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350 [No Abstract] [Full Text] [Related]
7. Collection and analysis of drug safety data in pregnancy. Moretti M Can J Clin Pharmacol; 2007; 14(1):e34-6. PubMed ID: 17213508 [No Abstract] [Full Text] [Related]
8. [Physician and pharmaceutical industry. II. Postmarketing surveillance]. Offerhaus L Ned Tijdschr Geneeskd; 1992 Jan; 136(1):36-41. PubMed ID: 1728761 [No Abstract] [Full Text] [Related]
10. ["There are clear criteria for product surveillance studies"]. Throm S MMW Fortschr Med; 2009 Aug; 151(34-35):7. PubMed ID: 19771777 [No Abstract] [Full Text] [Related]
11. With more follow-up. Prescrire Int; 2011 Feb; 20(113):32. PubMed ID: 21488585 [No Abstract] [Full Text] [Related]
12. [Critical analysis of the adverse effects reported to the Paris-Fernand Widal Drug Monitoring Center in a 2-month period]. Castot A; Carlier P; Lagier G; Elmalem J; Vincens M; Efthymiou M Therapie; 1986; 41(5):375-7. PubMed ID: 3810528 [No Abstract] [Full Text] [Related]
13. [Seventh French Drug Surveillance Seminar. Caen, 21-22 November 1985]. Therapie; 1986; 41(5):323-84. PubMed ID: 3810518 [No Abstract] [Full Text] [Related]
14. [Eighth French Drug Surveillance Seminar. Paris, 23-24 October 1986]. Therapie; 1987; 42(4):331-410. PubMed ID: 3686465 [No Abstract] [Full Text] [Related]
15. [Is imputation in drug surveillance reliable?]. Girard M Therapie; 1984; 39(3):291-6. PubMed ID: 6463954 [No Abstract] [Full Text] [Related]
16. [Is establishment of causality in drug surveillance reliable?]. Evreux JC Therapie; 1984; 39(4):437-8. PubMed ID: 6484888 [No Abstract] [Full Text] [Related]
17. [6th French seminar on drug surveillance. Clermont-Ferrand, 22-23 November 1984]. Therapie; 1985; 40(5):287-376. PubMed ID: 4095682 [No Abstract] [Full Text] [Related]
18. [4-year experience in drug surveillance]. CapellĂ D; Avila P; Cabeza L; Moreno V; Vidal X; Laporte JR Med Clin (Barc); 1988 Jun; 91(3):93-6. PubMed ID: 3172912 [No Abstract] [Full Text] [Related]
19. The drug safety review process. Somberg J Am J Ther; 2007; 14(2):119. PubMed ID: 17414577 [No Abstract] [Full Text] [Related]